
## Anne H Kallioniemi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8881743/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors. Science, 1992, 258, 818-821.	12.6	3,065
2	Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes and Cancer, 1994, 10, 231-243.	2.8	1,215
3	Breast-Cancer Risk in Families with Mutations in <i>PALB2</i> . New England Journal of Medicine, 2014, 371, 497-506.	27.0	745
4	Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nature Genetics, 2002, 31, 210-215.	21.4	410
5	A recurrent mutation in PALB2 in Finnish cancer families. Nature, 2007, 446, 316-319.	27.8	402
6	Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Research, 2002, 62, 6240-5.	0.9	352
7	Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes and Cancer, 1998, 21, 177-184.	2.8	313
8	Genome screening by comparative genomic hybridization. Trends in Genetics, 1997, 13, 405-409.	6.7	272
9	Detecting Activation of Ribosomal Protein S6 Kinase by Complementary DNA and Tissue Microarray Analysis. Journal of the National Cancer Institute, 2000, 92, 1252-1259.	6.3	251
10	Computer image analysis of comparative genomic hybridization. Cytometry, 1995, 19, 10-26.	1.8	250
11	Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes and Cancer, 1995, 12, 213-219.	2.8	198
12	NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nature Genetics, 2008, 40, 844-853.	21.4	181
13	Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15172-15177.	7.1	162
14	Frequent amplification of 8q24, 11q, 17q, and 20qâ€specific genes in pancreatic cancer. Genes Chromosomes and Cancer, 2002, 35, 353-358.	2.8	148
15	Genetic alterations in lobular breast cancer by comparative genomic hybridization. , 1997, 74, 513-517.		139
16	RAD51C is a susceptibility gene for ovarian cancer. Human Molecular Genetics, 2011, 20, 3278-3288.	2.9	124
17	Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. Cytometry, 1994, 16, 93-99.	1.8	116
18	High-Resolution Analysis of Gene Copy Number Alterations in Human Prostate Cancer Using CGH on cDNA Microarrays: Impact of Copy Number on Gene Expression. Neoplasia, 2004, 6, 240-247.	5.3	110

ANNE H KALLIONIEMI

#	Article	IF	CITATIONS
19	CGH microarrays and cancer. Current Opinion in Biotechnology, 2008, 19, 36-40.	6.6	107
20	A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7. Breast Cancer Research and Treatment, 2007, 103, 239-246.	2.5	106
21	High-Resolution Genomic and Expression Profiling Reveals 105 Putative Amplification Target Genes in Pancreatic Cancer. Neoplasia, 2004, 6, 432-439.	5.3	104
22	BMP7 influences proliferation, migration, and invasion of breast cancer cells. Cancer Letters, 2009, 275, 35-43.	7.2	102
23	Cloning of <i>BCAS3</i> (17q23) and <i>BCAS4</i> (20q13) genes that undergo amplification, overexpression, and fusion in breast cancerâ€. Genes Chromosomes and Cancer, 2002, 35, 311-317.	2.8	100
24	Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis?. Endocrine-Related Cancer, 2010, 17, R123-R139.	3.1	99
25	CGH-Plotter: MATLAB toolbox for CGH-data analysis. Bioinformatics, 2003, 19, 1714-1715.	4.1	98
26	The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2736-2741.	7.1	95
27	Amplification of a 280-Kilobase Core Region at the ERBB2 Locus Leads to Activation of Two Hypothetical Proteins in Breast Cancer. American Journal of Pathology, 2003, 163, 1979-1984.	3.8	90
28	Penetrance Analysis of the <i>PALB2</i> c.1592delT Founder Mutation. Clinical Cancer Research, 2008, 14, 4667-4671.	7.0	90
29	The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Research and Treatment, 2006, 95, 257-263.	2.5	89
30	Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. Cancer Genetics and Cytogenetics, 1998, 101, 53-57.	1.0	88
31	Bone morphogenetic protein 4—a fascinating regulator of cancer cell behavior. Cancer Genetics, 2012, 205, 267-277.	0.4	81
32	<i>CDK4</i> is a probable target gene in a novel amplicon at 12q13.3–q14.1 in lung cancer. Genes Chromosomes and Cancer, 2005, 42, 193-199.	2.8	76
33	Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer. BMC Genomics, 2008, 9, 348.	2.8	75
34	The diverse role of miRâ€31 in regulating cancer associated phenotypes. Genes Chromosomes and Cancer, 2013, 52, 1103-1113.	2.8	75
35	<i>HOXB13</i> G84E Mutation in Finland: Population-Based Analysis of Prostate, Breast, and Colorectal Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 452-460.	2.5	75
36	Increased copy number at 17q22-q24 by CGH in breast cancer is due to high-level amplification of two separate regions. , 1997, 20, 372-376.		74

3

ANNE H KALLIONIEMI

#	Article	IF	CITATIONS
37	Topoisomerase-IIα Is Upregulated in Malignant Peripheral Nerve Sheath Tumors and Associated With Clinical Outcome. Journal of Clinical Oncology, 2003, 21, 4586-4591.	1.6	74
38	Immunohistochemical Expression of DNA Repair Proteins in Familial Breast Cancer Differentiate <i>BRCA2</i> -Associated Tumors. Journal of Clinical Oncology, 2005, 23, 7503-7511.	1.6	70
39	Intersex-like (IXL) Is a Cell Survival Regulator in Pancreatic Cancer with 19q13 Amplification. Cancer Research, 2007, 67, 1943-1949.	0.9	68
40	Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4. Breast Cancer Research and Treatment, 2010, 124, 377-386.	2.5	68
41	Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer. Genes Chromosomes and Cancer, 2006, 45, 411-419.	2.8	67
42	High-Throughput Copy Number Analysis of 17q23 in 3520 Tissue Specimens by Fluorescence in Situ Hybridization to Tissue Microarrays. American Journal of Pathology, 2002, 161, 73-79.	3.8	66
43	High-Resolution Analysis of Gene Copy Number Alterations in Human Prostate Cancer Using CGH on cDNA Microarrays: Impact of Copy Number on Gene Expression. Neoplasia, 2004, 6, 240-247.	5.3	62
44	Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. Cancer Genetics and Cytogenetics, 2000, 123, 128-132.	1.0	60
45	Improved procedure for fluorescence in situ hybridization on tissue microarrays. Cytometry, 2001, 45, 83-86.	1.8	60
46	Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. Oncogene, 2004, 23, 1010-1013.	5.9	59
47	Breast Cancer–Associated <i>Abraxas</i> Mutation Disrupts Nuclear Localization and DNA Damage Response Functions. Science Translational Medicine, 2012, 4, 122ra23.	12.4	54
48	BMP4 inhibits the proliferation of breast cancer cells and induces an MMP-dependent migratory phenotype in MDA-MB-231 cells in 3D environment. BMC Cancer, 2013, 13, 429.	2.6	51
49	A physical map of chromosome 20 established using fluorescence in situ hybridization and digital image analysis. Genomics, 1995, 26, 134-137.	2.9	50
50	Pancreatic adenocarcinoma—Genetic portrait from chromosomes to microarrays. Genes Chromosomes and Cancer, 2006, 45, 721-730.	2.8	50
51	Bone morphogenetic protein 4 expression in multiple normal and tumor tissues reveals its importance beyond development. Modern Pathology, 2013, 26, 10-21.	5.5	50
52	Hypermethylated MAL gene – a silent marker of early colon tumorigenesis. Journal of Translational Medicine, 2008, 6, 13.	4.4	48
53	Gene Copy Number Analysis by Fluorescencein SituHybridization and Comparative Genomic Hybridization. Methods, 1996, 9, 113-121.	3.8	44
54	Title is missing!. Machine Learning, 2003, 52, 45-66.	5.4	44

4

## Anne H Kallioniemi

#	Article	IF	CITATIONS
55	Characterization of the 7q21â€q22 amplicon identifies ARPC1A, a subunit of the Arp2/3 complex, as a regulator of cell migration and invasion in pancreatic cancer. Genes Chromosomes and Cancer, 2009, 48, 330-339.	2.8	44
56	PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53. Cancer Genetics and Cytogenetics, 2008, 182, 33-39.	1.0	42
57	Bone morphogenetic protein â^'4 and â^'5 in pancreatic cancer—Novel bidirectional players. Experimental Cell Research, 2011, 317, 2136-2146.	2.6	42
58	Clinical and functional target validation using tissue and cell microarrays. Current Opinion in Chemical Biology, 2002, 6, 97-101.	6.1	41
59	A Finnish founder mutation in <i>RAD51D</i> : analysis in breast, ovarian, prostate, and colorectal cancer: Table 1. Journal of Medical Genetics, 2012, 49, 429-432.	3.2	41
60	Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients. Oncotarget, 2014, 5, 3076-3087.	1.8	35
61	Concomitant gastrin and ERBB2 gene amplifications at 17q12-q21 in the intestinal type of gastric cancer. , 1999, 24, 24-29.		33
62	Both inhibition and enhanced expression of miRâ€31 lead to reduced migration and invasion of pancreatic cancer cells. Genes Chromosomes and Cancer, 2012, 51, 557-568.	2.8	32
63	Identification of differentially expressed genes after PPM1D silencing in breast cancer. Cancer Letters, 2008, 259, 61-70.	7.2	28
64	Rare Copy Number Variants Observed in Hereditary Breast Cancer Cases Disrupt Genes in Estrogen Signaling and TP53 Tumor Suppression Network. PLoS Genetics, 2012, 8, e1002734.	3.5	28
65	Molecular Signatures of Breast Cancer — Predicting the Future. New England Journal of Medicine, 2002, 347, 2067-2068.	27.0	26
66	Frequent amplification and overexpression of CCND1 in male breast cancer. International Journal of Cancer, 2004, 111, 968-971.	5.1	26
67	FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population. Breast Cancer Research and Treatment, 2017, 166, 217-226.	2.5	26
68	RAD51B in Familial Breast Cancer. PLoS ONE, 2016, 11, e0153788.	2.5	26
69	Molecular cytogenetics: Diagnosis and prognostic assessment. Current Opinion in Biotechnology, 1992, 3, 623-631.	6.6	25
70	19q13 amplification is associated with high grade and stage in pancreatic cancer. Genes Chromosomes and Cancer, 2010, 49, 569-575.	2.8	25
71	Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication. BMC Cancer, 2010, 10, 181.	2.6	24
72	Characterization of Non-Specific Cytotoxic Cell Receptor Protein 1: A New Member of the Lectin-Type Subfamily of F-Box Proteins. PLoS ONE, 2011, 6, e27152.	2.5	24

Anne H Kallioniemi

#	Article	IF	CITATIONS
73	From chromosomal alterations to target genes for therapy: integrating cytogenetic and functional genomic views of the breast cancer genome. Seminars in Cancer Biology, 2001, 11, 395-401.	9.6	22
74	Analysis of BMP4 and BMP7 signaling in breast cancer cells unveils time-dependent transcription patterns and highlights a common synexpression group of genes. BMC Medical Genomics, 2011, 4, 80.	1.5	22
75	Effects of Cytokine Activation and Oxidative Stress on the Function of the Human Embryonic Stem Cell–Derived Retinal Pigment Epithelial Cells. , 2015, 56, 6265.		22
76	The impact of bone morphogenetic protein 4 (BMP4) on breast cancer metastasis in a mouse xenograft model. Cancer Letters, 2016, 375, 238-244.	7.2	22
77	The expression patterns of gremlin 1 and noggin in normal adult and tumor tissues. International Journal of Clinical and Experimental Pathology, 2013, 6, 1400-8.	0.5	22
78	A strategy for identifying putative causes of gene expression variation in human cancers. Journal of the Franklin Institute, 2004, 341, 77-88.	3.4	21
79	Large genomic BRCA2 rearrangements and male breast cancer. Cancer Detection and Prevention, 2006, 30, 530-534.	2.1	21
80	KPNA7, a nuclear transport receptor, promotes malignant properties of pancreatic cancer cells in vitro. Experimental Cell Research, 2014, 322, 159-167.	2.6	21
81	<i>PLA2G7</i> associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelialâ€mesenchymal transition in cultured breast cancer cells. Journal of Pathology: Clinical Research, 2017, 3, 123-138.	3.0	20
82	Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility. Scientific Reports, 2017, 7, 681.	3.3	20
83	Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer. BMC Cancer, 2018, 18, 1045.	2.6	20
84	Recurrent moderateâ€risk mutations in Finnish breast and ovarian cancer patients. International Journal of Cancer, 2019, 145, 2692-2700.	5.1	19
85	MED29, a component of the mediator complex, possesses both oncogenic and tumor suppressive characteristics in pancreatic cancer. International Journal of Cancer, 2011, 129, 2553-2565.	5.1	18
86	Depletion of nuclear import protein karyopherin alpha 7 (KPNA7) induces mitotic defects and deformation of nuclei in cancer cells. BMC Cancer, 2018, 18, 325.	2.6	14
87	FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome. International Journal of Cancer, 2016, 139, 2760-2770.	5.1	13
88	Search for KPNA7 cargo proteins in human cells reveals MVP and ZNF414 as novel regulators of cancer cell growth. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 211-219.	3.8	13
89	Bone morphogenetic protein 4 regulates micro <scp>RNA</scp> expression in breast cancer cell lines in diverse fashion. Genes Chromosomes and Cancer, 2016, 55, 227-236.	2.8	11
90	Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells <i>In Vitro</i> . Anticancer Research, 2020, 40, 3129-3138.	1.1	11

ANNE H KALLIONIEMI

#	Article	IF	CITATIONS
91	Amplifications of oncogeneerbB-2 and chromosome 20q in breast cancer determined by differentially competitive polymerase chain reaction. Breast Cancer Research and Treatment, 1996, 40, 271-281.	2.5	10
92	Search for large genomic alterations of the BRCA1 gene in a Finnish population. Cancer Genetics and Cytogenetics, 2005, 163, 57-61.	1.0	10
93	Transcription factors—Intricate players of the bone morphogenetic protein signaling pathway. Genes Chromosomes and Cancer, 2018, 57, 3-11.	2.8	8
94	Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Endometrial Cancer Cells In Vitro. Anticancer Research, 2017, 37, 6575-6581.	1.1	8
95	Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families. BMC Cancer, 2017, 17, 496.	2.6	7
96	Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes and Cancer, 1998, 21, 177-184.	2.8	7
97	DNA Copy Number Analysis on Tissue Microarrays. Methods in Molecular Biology, 2010, 664, 127-134.	0.9	6
98	Mutations in the BRCA2 interacting DSS1 are not a risk factor for male breast cancer. International Journal of Cancer, 2007, 120, 444-446.	5.1	4
99	Wound healing of human embryonic stem cell-derived retinal pigment epithelial cells is affected by maturation stage. BioMedical Engineering OnLine, 2018, 17, 102.	2.7	4
100	A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients. Scientific Reports, 2021, 11, 14763.	3.3	3
101	Genetic alterations in lobular breast cancer by comparative genomic hybridization. International Journal of Cancer, 1997, 74, 513-517.	5.1	3
102	Molecular cytogenetics of primary breast cancer by CGH. , 1998, 21, 177.		2
103	Evaluation of the RHINO gene for breast cancer predisposition in Finnish breast cancer families. Breast Cancer Research and Treatment, 2014, 144, 437-441.	2.5	1
104	Novel ZNF414 activity characterized by integrative analysis of ChIP-exo, ATAC-seq and RNA-seq data. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2022, 1865, 194811.	1.9	1